Compounds for the treatment of neurodegenerative and metabolic disorders
Summary
USPTO granted Patent US12590094B2 to University of Florida Research Foundation for heterocyclic compounds targeting neurodegenerative diseases linked to protein misfolding, including Alzheimer's, Parkinson's, ALS, and prion diseases, as well as metabolic disorders. The patent covers 8 lead compound series demonstrating NAD-restoring properties and therapeutic efficacy in cellular and animal models.
What changed
USPTO granted Patent US12590094B2 to the University of Florida Research Foundation, covering heterocyclic compounds for treating neurodegenerative and metabolic disorders. The 5 granted claims relate to compounds that restore NAD levels, addressing conditions including Alzheimer's disease, Parkinson's disease, ALS, prion diseases, diabetes mellitus, and brain ischemia/reperfusion injury. The compounds were developed by inventors Corinne Lasmézas, Minghai Zhou, and Thomas D. Bannister, with filing date May 14, 2020.
This patent grant establishes exclusive IP rights for the University of Florida Research Foundation. Pharmaceutical companies and researchers developing NAD-restoring therapies should review this patent landscape to identify potential licensing opportunities or design-around strategies. Patients and healthcare providers may see future therapeutic developments in these treatment areas. No immediate compliance actions are required, but patent monitoring is advisable for entities in the neurodegenerative disease drug development space.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compounds for the treatment of neurodegenerative and metabolic disorders
Grant US12590094B2 Kind: B2 Mar 31, 2026
Assignee
University of Florida Research Foundation, Incorporated
Inventors
Corinne Lasmézas, Minghai Zhou, Thomas D. Bannister
Abstract
Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimer's disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia/reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and/or animal models of prion disease, PD and ALS.
CPC Classifications
C07D 487/04 C07D 217/04 C07D 217/10 C07D 277/42 C07D 311/30 C07D 401/16 C07D 401/14 C07D 405/14 C07D 413/14 C07D 417/04 C07D 471/04 C07D 513/04 C07H 17/07
Filing Date
2020-05-14
Application No.
17610758
Claims
5
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.